X4 Pharmaceuticals, Inc.
Assets & Liabilities
| Period | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| Mar 2017 | — | — | $2.3M |
| Jun 2017 | — | — | $24.1M |
| Sep 2017 | — | — | $26.3M |
| Dec 2017 | $22.5M | $81.3M | $26.7M |
| Mar 2018 | $20.8M | $69.2M | $64.0M |
| Jun 2018 | $19.4M | $57.2M | $12.6M |
| Sep 2018 | $18.0M | $45.9M | $9.8M |
| Dec 2018 | $21.6M | $9.9M | $8.1M |
| Mar 2019 | $33.1M | $62.5M | $22.3M |
| Jun 2019 | $37.3M | $133.5M | $90.2M |
| Sep 2019 | $30.4M | $109.5M | $76.3M |
| Dec 2019 | $31.5M | $160.7M | $126.2M |
| Mar 2020 | $34.9M | $153.7M | $115.1M |
| Jun 2020 | $37.7M | $142.5M | $103.7M |
| Sep 2020 | $43.4M | $133.1M | $88.8M |
| Dec 2020 | $50.1M | $122.9M | $78.7M |
| Mar 2021 | $54.1M | $161.0M | $114.9M |
| Jun 2021 | $52.4M | $141.7M | $95.2M |
| Sep 2021 | $51.8M | $120.5M | $76.4M |
| Dec 2021 | $52.8M | $117.2M | $81.8M |
| Mar 2022 | $49.9M | $99.6M | $66.4M |
| Jun 2022 | $50.9M | $81.0M | $47.4M |
| Sep 2022 | $51.6M | $113.4M | $79.9M |
| Dec 2022 | $81.5M | $155.6M | $121.7M |
| Mar 2023 | $72.7M | $124.4M | $93.4M |
| Jun 2023 | $105.9M | $173.4M | $136.4M |
| Sep 2023 | $105.7M | $173.3M | $131.6M |
| Dec 2023 | $96.2M | $147.3M | $99.2M |
| Mar 2024 | $111.1M | $112.2M | $60.5M |
| Jun 2024 | $116.2M | $210.6M | $147.2M |
| Sep 2024 | $118.5M | $178.2M | $97.4M |
| Dec 2024 | $124.3M | $146.4M | $55.7M |
| Mar 2025 | $107.1M | $130.0M | $40.3M |
| Jun 2025 | $101.2M | $105.2M | $39.2M |
| Sep 2025 | $101.9M | $163.6M | $69.6M |
| Dec 2025 | $104.2M | $290.5M | $217.0M |
| Mar 2026 | $101.8M | $270.3M | $216.9M |
| Jun 2026 | $97.6M | $253.1M | $195.1M |